Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults

NCT04249830 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of the CliniMACS® TCRαβ-Biotin System and CliniMACS® CD19 is to improve the safety and efficacy of allogeneic HLA-partially matched related or unrelated donors HSCT when no matched donors are available, to treat malignant and nonmalignant disorders for which HSCT is the recommended best available therapy. Initially this device will be used in a single-center, open-label, single-arm, phase II clinical trial to evaluate the efficacy of haploidentical PBSC grafts depleted of TCRα/β+ and CD19+ cells using the CliniMACS® TCRαβ/CD19 System in children and adults with hematological and non-hematological malignancies.

Conditions Studied

Interventions

  • BIOLOGICAL Allogeneic Stem Cell Transplant
  • DEVICE CliniMACS TCR α/β Reagent Kit and CliniMACS CD19

Study Locations (1)

California

  • Lucile Packard Children's Hospital — Palo Alto

Trial Details

FieldValue
Enrollment Target 204 participants
Start Date 2020-02-01
Est. Completion 2030-12
Phase NA

Sponsor

Alice Bertaina

2 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04249830

The ClinicalTrials.gov registry entry for NCT04249830 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 204 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alice Bertaina, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Hematologic Diseases appearing as the primary indexed condition, and to 2 interventions — of which Allogeneic Stem Cell Transplant is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04249830 reports 1 study location spanning 1 distinct geographic area — top geographies include California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04249830 about?

NCT04249830 is a clinical study titled "Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults". The purpose of the CliniMACS® TCRαβ-Biotin System and CliniMACS® CD19 is to improve the safety and efficacy of allogeneic HLA-partially matched related or unrelated donors HSCT when no matched donors are available, to treat malignant and nonmalignant disorders for which HSCT is the recommended best ...

What is the current status of trial NCT04249830?

This trial is currently recruiting. It is a NA study. The enrollment target is 204 participants. The study started on 2020-02-01. Estimated completion is 2030-12.

What conditions does trial NCT04249830 study?

This clinical trial studies the following conditions: Hematologic Diseases. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04249830?

The interventions under investigation include: Allogeneic Stem Cell Transplant (BIOLOGICAL), CliniMACS TCR α/β Reagent Kit and CliniMACS CD19 (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04249830?

This trial is sponsored by Alice Bertaina, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04249830 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial